SANDRA J. HORNING, M.D. - Corporate Board Profile

GILEAD SCIENCES, INC.

Filing Date	Source Excerpt
2020-03-24	Sandra J. Horning, M.D. Dr. Horning was the Chief Medical Officer and Global Head of Product Development of Roche, Inc., until her retirement in 2019. During her 10-year career at Roche and Genentech, she helped bring 15 new medicines to patients in disease areas including cancer, multiple sclerosis, influenza and blindness. Prior to her career at Roche, Dr. Horning spent 25 years as a practicing oncologist, investigator and tenured professor at Stanford University School of Medicine, where she remains a professor of medicine emerita. From 2005 to 2006, she served as President of the American Society of Clinical Oncology. Dr. Horning was recognized as the 2020 Healthcare Businesswomen’s Association Woman of the Year. She was also selected as the 2017 recipient of the Duane Roth Memorial Award, an honor dedicated to leaders in healthcare, whose work has overcome numerous scientific obstacles to create new paradigms in research and treatment. From 2015 to 2018, Dr. Horning served on the board of directors of Foundation Medicine. She currently serves as an advisor to EQRx.
2021-03-30	Sandra J. Horning, M.D. New INDEPENDENT AGE: 72 DIRECTOR SINCE: 2020 COMMITTEES: Nominating and Corporate Governance, Science EFFECTIVE MAY 2021: Science (Chair) Dr. Horning joined our Board in January 2020. ... Our Board unanimously recommends a vote FOR each named director nominee: Sandra J. Horning ... 2020 Director Compensation ... Sandra J. Horning $159,014 cash, $190,657 options, $191,368 RSUs, total $541,039.
2022-03-24	Sandra J. Horning, M.D. Independent Dr. Horning joined our Board in January 2020. Dr. Horning was the Chief Medical Officer and Global Head of Product Development of Roche, Inc., until her retirement in 2019. During her 10-year career at Roche and Genentech, she helped bring 15 new medicines to patients in disease areas including cancer, multiple sclerosis, influenza and blindness. Prior to her career at Roche, Dr. Horning spent 25 years as a practicing oncologist, investigator and tenured professor at Stanford University School of Medicine, where she remains a professor of medicine emerita. From 2005 to 2006, she served as President of the American Society of Clinical Oncology. Dr. Horning was recognized as the 2020 Healthcare Businesswomen’s Association Woman of the Year. She was also selected as the 2017 recipient of the Duane Roth Memorial Award, an honor dedicated to leaders in healthcare, whose work has overcome numerous scientific obstacles to create new paradigms in research and treatment. From 2015 to 2018, Dr. Horning served on the Foundation Medicine Board of Directors. She currently serves on the board of directors of Moderna, Inc., Olema Pharmaceuticals, Inc. and EQRx, Inc. Relevant Skills And Experience: Significant leadership experience in the pharmaceutical and healthcare industry, including expertise in drug development in multiple therapeutic areas. Medical professional with experience treating patients as a practicing oncologist. Other Public Company Board Service: ● Moderna, Inc. ● Olema Pharmaceuticals, Inc. ● EQRx, Inc. 2021 Director Compensation The table below summarizes the compensation paid by us to our non-employee Board members for the 2021 fiscal year: Sandra J. Horning $67,589 Fees Earned or Paid in Cash $149,941 Stock Awards $149,991 Option Awards $367,521 Total
2023-03-23	Sandra J. Horning, M.D. Independent Dr. Horning joined our Board in January 2020. Dr. Horning was the Chief Medical Officer and Global Head of Product Development of Roche, Inc., until her retirement in 2019. During her 10-year career at Roche and Genentech, she helped bring 15 new medicines to patients in disease areas including cancer, multiple sclerosis, influenza and blindness. Prior to her career at Roche, Dr. Horning spent 25 years as a practicing oncologist, investigator and tenured professor at Stanford University School of Medicine, where she remains a professor of medicine emerita. From 2005 to 2006, she served as President of the American Society of Clinical Oncology. Dr. Horning was recognized as the 2020 Healthcare Businesswomen’s Association Woman of the Year. She was also selected as the 2017 recipient of the Duane Roth Memorial Award, an honor dedicated to leaders in healthcare, whose work has overcome numerous scientific obstacles to create new paradigms in research and treatment. Dr. Horning previously served on the board of directors of Foundation Medicine from 2015 to 2018. She currently serves on the board of directors of Moderna, Inc., Olema Pharmaceuticals, Inc. and EQRx, Inc. Relevant Skills and Experience: Significant leadership experience in the pharmaceutical and healthcare industry, including expertise in drug development in multiple therapeutic areas. Medical professional with experience treating patients as a practicing oncologist. Other Public Company Board Service: Moderna, Inc. Olema Pharmaceuticals, Inc. EQRx, Inc. 2022 Director Compensation Sandra J. Horning $130,000 cash + $149,939 stock awards + $149,993 option awards = $429,932 total annual compensation.
2024-03-28	Sandra J. Horning, M.D. Age 75 Director Since 2020 Committees: Nominating and Corporate Governance, Science (Chair) Other Public Company Board Service: Moderna, Inc., Olema Pharmaceuticals, Inc., Revolution Medicines, Inc.
2025-03-27	Sandra J. Horning, M.D. Independent Age: 76 Director since: 2020 Committees: ► Nominating and Corporate Governance ► Science (Chair) 2024 Director Compensation Sandra J. Horning, M.D. Fees Earned or Paid in Cash 130,000 Stock Awards 149,965 Option Awards 149,995 All Other Compensation — Total 429,960